does medicare part d cover tirzepatide Weight-Loss Medications Like Zepbound or Wegovy? The Medicare prescription drug coverage

For brand manufacturers managing lifecycle transitions, the analytical priority is identifying which drugs in the portfolio are Cost Plus-vulnerable meaning they have generic or biosimilar competitors with APIs available at manufacturing cost that Cost Plus could list at prices far below current protected pricing and which drugs have genuine clinical differentiation that would withstand direct cost-plus price competition

They improve access

Of course, theres a difference between helpful alterations in taste and dysgeusia, where everything tastes so yucky that you cant get enough nutrients

Combined revenue from those two products reached $12.8 billion in Q1 2026, representing $6.7 billion in year-over-year growth